

## Diaceutics Launches Enhanced Rare-Disease Offering

*Significant expansion of lab network will deliver more rare-disease data*

*New contract signed to support the commercialisation of a rare-disease therapy*

**Belfast and London, 27 August 2024** - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging cutting-edge data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes.

Driving this enhancement are 3 key developments within the Diaceutics business as follows:

- 1. Onboarding of New Data Partners:** A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the largest recognised testing lab in the United States for genetically acquired rare diseases.
- 2. Advanced Lab Labelling Natural Language Processing (NLP):** Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify.
- 3. Access to Additional Industry Experts:** The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering.

**Jordan Clark, Chief Data Officer of Diaceutics commented:** *"These enhancements to our rare-disease data offering represent significant progress in our mission to support the earlier identification and treatment of patients with rare diseases. By integrating new data, advanced labelling and a specialised team, we are well-positioned to address the critical needs of this underserved market and help patients in need."*

**Susanne Munksted, Chief Precision Medicine Officer of Diaceutics, commented:** *"Diaceutics is uniquely positioned to support pharma clients in the challenging and complex area of rare diseases. Our business model is unique in that we combine best in class data with disease experts who have a passion for precision medicine and improving patient outcomes."*

Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need.

The strategic enhancements announced today will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

### About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

### Enquiries:

#### Diaceutics PLC

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
investorrelations@diaceutics.com

#### Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison, Nick Harland, Kate Hanshaw

Tel: +44 (0)20 7710 7600

#### Alma Strategic Communications

Caroline Forde, Kinvara Verdon, Kieran Breheny

Tel: +44(0)20 3405 0205  
diaceutics@almastrategic.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFIFTTVIVFIS